Dr. Yoshinobu Baba is Professor of Department of Applied Chemistry, Graduate School of Engineering, Nagoya University. He is also a Director of FIRST Research Center for Innovative Nanobiodevices, Nagoya University and a Director of Synchrotron Radiation Research Center, Nagoya University. He is an Associate Editor of Anal. Chem. of American Chemical Society and serving to over 20 scientific journals, including Nanoscale of Royal Society of Chemistry and Biomicrofluidics of American Institute of Physics, as an editorial/advisory board member. He is a co-initiator for the world largest Nanotech/Nanobio International Meeting and Exhibition in Japan and International Academy of Nanomedicine. He is a general chair of numerous international meetings (microTAS, MSB, NanoBioEXPO, ISMM). He has been admitted as a Fellow of the Royal Society of Chemistry and received over 113 awards for his contributions in nanobiotechnology: MERCK Award in 2004, award from the Applied Physics Society of Japan in 2006, and The CSJ (Chemical Society of Japan) award for creative work in 2008. His major area of interest is nanobiosicence and nanobiotechnology for omics, systems biology, medical diagnosis, tissue engineering, and molecular imaging. He is the author or co-author of 767 publications, including research papers, proceedings, reviews, and books and is also an inventor of over 70 patents. He has delivered more than 726 plenary and invited lectures at conferences. His work has been cited on 299 occasions by newspapers and televisions.
Nanobiodevices, Quantum Life Science, and AI for Future Healthcare
Thursday, 5 October 2023 at 09:30
Add to Calendar ▼2023-10-05 09:30:002023-10-05 10:30:00Europe/LondonNanobiodevices, Quantum Life Science, and AI for Future HealthcareLab-on-a-Chip and Microfluidics Asia 2023 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
We have investigated nanobiodevices, quantum life science, and AI for biomedical applications and healthcare. Nanowire devices are extremely useful to isolate extracellular vesicles from body fluids and vesicle-encapsulated microRNA analysis. The device composed of a microfluidic substrate with anchored nanowires gives us highly efficient collections of extracellular vesicles in body fluids and in situ extraction for huge numbers of miRNAs (2,500 types) more than the conventional ultracentrifugation method. Nanowire devices gave us the miRNA date for several hundred patients and machine learning system based on these miRNA data enabled us to develop the early-stage diagnosis for lung cancer, brain tumor, pancreas cancer, liver cancer, bladder cancer, prostate cancer, diabetes, heart diseases, and Parkinson disease. Nanowire-nanopore devices combined with AI (machine learning technique) enable us to develop mobile sensors for SARS-CoV-2, PM2.5, bacteria, and virus in the environment. MEXT Quantum Leap Flagship Program (Q-LEAP), which I lead, has been developing biological nano quantum sensors, quantum technology-based MRI/NMR, and quantum biology and biotechnology. Nanodiamonds, with nitrogen-vacancy centers, and quantum dots are applied to develop quantum sensors for quantum switching intra vital imaging for iPS cell (induced pluripotent stem cells) based regenerative medicine, and quantum photo immuno-therapeutic devices for cancer. Multifunctional quantum nanoparticles were developed for fluorescence/MR bimodal in vivo imaging-guided potothermal-intensified chemodynamic synergetic therapy of targeted tumors.
Add to Calendar ▼2023-10-05 00:00:002023-10-06 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Asia 2023Lab-on-a-Chip and Microfluidics Asia 2023 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-10-05 09:30:002023-10-05 10:30:00Europe/LondonNanobiodevices, Quantum Life Science, and AI for Future HealthcareLab-on-a-Chip and Microfluidics Asia 2023 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
